Efficacy and Safety of More Intensive Lowering of LDL Cholesterol: A Meta-Analysis of 26 Randomised Trials

This is one of the bedrock documents of modern cardiology — the Cholesterol Treatment Trialists’ analysis that turned dozens of separate statin trials into a single, unanswerable conclusion about LDL cholesterol.

Pooling individual data from over 169,000 patients across 26 randomized trials, the collaborators found a clean linear law: every 1 mmol/L (about 39 mg/dL) reduction in LDL cholesterol cut major vascular events by 22 percent, and all-cause mortality by 10 percent. Two features made it decisive. First, the benefit held at every baseline LDL level, including patients who started below 2.0 mmol/L — there was no floor below which lowering stopped helping. Second, more intensive therapy beat less intensive therapy, extending the same relationship further down. And the safety signal was reassuring: no increase in cancer or non-vascular death.

The practical distillation is the phrase the field now repeats: it is the absolute amount of LDL lowering, applied to a patient’s absolute risk, that determines benefit. Lower is better, with no apparent threshold.

We rate the evidence at the very top of this library. An individual-patient meta-analysis of this scale and rigor is the strongest form of evidence in clinical medicine, and it underpins essentially every cholesterol guideline since.